Sensus Healthcare 향후 성장
Future 기준 점검 2/6
Sensus Healthcare은 연간 수입과 매출이 각각 87.3%와 20.3% 증가할 것으로 예상되고 EPS는 연간 87.9%만큼 증가할 것으로 예상됩니다.
핵심 정보
87.3%
이익 성장률
87.88%
EPS 성장률
| Medical Equipment 이익 성장 | 16.2% |
| 매출 성장률 | 20.3% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 18 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Jun 04
SRTS: 2026 Reimbursement Codes Will Support Long Term Earnings Potential
Analysts have reduced their price target on Sensus Healthcare by $1 to $6, reflecting a lower fair value estimate and sharply reduced profit margin assumptions, partly offset by expectations for continued revenue growth from the SRT platform, supported by new reimbursement codes planned for 2026. Analyst Commentary Recent research points to a more cautious tone around Sensus Healthcare, with the trimmed price target reflecting reduced profit margin assumptions, even as analysts still factor in potential revenue contribution from the SRT platform and future reimbursement changes planned for 2026.
내러티브 업데이트 • May 19
SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset
Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.
내러티브 업데이트 • Apr 25
SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside
Narrative Update Overview Analysts have trimmed their average price target on Sensus Healthcare from $8.00 to $7.50, reflecting mixed views that balance expectations for stronger SRT platform revenue supported by new 2026 reimbursement codes, alongside the impact of recent quarterly results that fell short due to no sales from a key customer. Analyst Commentary Bullish analysts remain constructive on Sensus Healthcare, pointing to the company’s SRT platform and upcoming reimbursement changes as key elements that could support long term growth.내러티브 업데이트 • Apr 10
SRTS: 2026 Reimbursement Shift Will Support Future Skin Therapy Adoption
Analysts have updated the price target range for Sensus Healthcare. One analyst raised the target to $7.50, citing expectations for SRT platform revenue supported by new 2026 reimbursement codes.내러티브 업데이트 • Mar 27
SRTS: Reimbursement Shift In 2026 Will Drive Future Upside Potential
Narrative Update: Sensus Healthcare (SRTS) The blended analyst price target for Sensus Healthcare has shifted from $8 to $7.50. Analysts are balancing expectations for very strong SRT platform revenue in 2026, tied to new reimbursement codes, with the impact of Q4 results that missed forecasts due to no sales from the company’s largest customer.내러티브 업데이트 • Mar 10
SRTS: Future Upside Will Depend On 2026 Reimbursement Code Changes
Analysts have nudged their fair value estimate for Sensus Healthcare slightly higher to $6.88, reflecting mixed recent research in which one firm trimmed its price target to $6 after weak Q4 results, while another initiated coverage with a more upbeat $7.50 target tied to expectations for the SRT platform and 2026 reimbursement changes. Analyst Commentary Bullish Takeaways Bullish analysts point to the SRT-100/Vision platform as the core driver of the current fair value view, given its focus on treating both oncological and non-oncological skin conditions, which supports their more constructive stance on long term growth potential.내러티브 업데이트 • Feb 24
SRTS: Future Upside Will Hinge On Reducing Largest Customer Concentration Risk
Narrative Update on Sensus Healthcare Analysts have trimmed their price target on Sensus Healthcare to $6 from $8, pointing to Q4 results that came in well below their expectations after the company reported no sales from its largest customer. Analyst Commentary Analysts are adjusting their views on Sensus Healthcare after the latest Q4 report, with the lower price target reflecting both execution concerns and how the market may now be valuing the shares.분석 기사 • Feb 15
Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates
As you might know, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) last week released its latest annual, and things did not...내러티브 업데이트 • Feb 10
SRTS: Auditor Transition And Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Sensus Healthcare to US$20.65 from US$21.29, reflecting updated assumptions that include slightly higher projected revenue growth, a modestly stronger profit margin profile, and a marginally lower future P/E multiple. What's in the News Auditor change: Sensus Healthcare's Audit Committee dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP and approved Carr, Riggs & Ingram, LLC as the new independent registered public accounting firm following CRI's acquisition of certain BPB capital markets assets, effective January 1, 2026 (Key Developments).내러티브 업데이트 • Jan 25
SRTS: Slightly Improved Outlook And Auditor Transition Will Support Future Upside
Analysts have raised their price target on Sensus Healthcare by a small amount, citing slightly higher assumptions for revenue growth and profit margins, along with a modestly lower discount rate and a marginally reduced future P/E multiple. What's in the News The Audit Committee of Sensus Healthcare's Board of Directors dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent registered public accounting firm and approved Carr, Riggs & Ingram, LLC as the new auditor, following CRI's acquisition of certain capital markets assets from BPB effective January 1, 2026 (company filing).분석 기사 • Jan 14
Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares have been powering on, with a gain of 38...내러티브 업데이트 • Jan 10
SRTS: Keloid Treatment Breakthrough Will Support Stronger Prospects Despite Trimmed Outlook
Narrative Update on Sensus Healthcare Analysts have modestly raised their price target on Sensus Healthcare, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E. Together, these adjustments support a higher fair value estimate now framed at US$8.00.내러티브 업데이트 • Dec 26
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have modestly lifted their price target on Sensus Healthcare to reflect slightly faster expected revenue growth and improving profit margins, even as they temper future valuation multiples. Valuation Changes Discount Rate has risen slightly from 7.69% to 7.70%, reflecting a marginally higher required return.내러티브 업데이트 • Dec 12
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have trimmed their price target on Sensus Healthcare to approximately 8 dollars from about 10 dollars, citing softer expected revenue growth, lower projected profit margins, and a higher assumed future price to earnings multiple that together point to a more conservative valuation outlook. What's in the News Peer reviewed data from a single center retrospective study in Dermatologic Therapy show that Sensus Healthcare's superficial radiotherapy technology combined with punch excision significantly improved keloid outcomes over one year, including reductions in pain, itching, thickness and irregularity of scars, with no severe adverse reactions reported (study in Dermatologic Therapy).분석 기사 • Nov 19
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rockets 26% But Many Are Still Ignoring The Company
The Sensus Healthcare, Inc. ( NASDAQ:SRTS ) share price has done very well over the last month, posting an excellent...분석 기사 • Oct 04
Insufficient Growth At Sensus Healthcare, Inc. (NASDAQ:SRTS) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) is a stock...내러티브 업데이트 • Sep 04
Increased CMS Reimbursement And International Expansion Will Unlock Demand
With no new analyst reasoning provided and both the discount rate and future P/E ratio remaining stable, the consensus fair value for Sensus Healthcare is unchanged at $8.00. What's in the News Sensus Healthcare's entire superficial radiation therapy (SRT) system portfolio received Medical Device Single Audit Program (MDSAP) certification.분석 기사 • Jul 12
Returns On Capital Are Showing Encouraging Signs At Sensus Healthcare (NASDAQ:SRTS)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...분석 기사 • May 06
Why Sensus Healthcare, Inc. (NASDAQ:SRTS) Could Be Worth Watching
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it received a lot of...분석 기사 • Mar 13
Investors Shouldn't Be Too Comfortable With Sensus Healthcare's (NASDAQ:SRTS) Earnings
Despite posting some strong earnings, the market for Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) stock hasn't moved much...분석 기사 • Feb 25
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares are down a considerable 27% in...분석 기사 • Feb 08
Revenue Beat: Sensus Healthcare, Inc. Beat Analyst Estimates By 5.6%
Shareholders in Sensus Healthcare, Inc. ( NASDAQ:SRTS ) had a terrible week, as shares crashed 29% to US$5.84 in the...새로운 내러티브 • Jan 07
SRTS Market Outlook
Sensus Healthcare (NASDAQ: SRTS) operates in the Healthcare sector and is part of the Medical Devices industry. Specifically, it focuses on the development and commercialization of non-invasive Superf분석 기사 • Dec 18
We Think Sensus Healthcare (NASDAQ:SRTS) Might Have The DNA Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...분석 기사 • Nov 19
Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders of Sensus Healthcare, Inc. ( NASDAQ:SRTS ) will be pleased this week, given that the stock price is up 19...분석 기사 • Nov 12
Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
It's not a stretch to say that Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) price-to-earnings (or "P/E") ratio of 17.4x...분석 기사 • Oct 03
At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it saw a significant share...
새로운 내러티브 • Sep 28
Fair Deal Agreement And Global Expansion Set To Revolutionize Revenue And Margins
Strategic shift towards recurring revenue with the Fair Deal Agreement model indicates potential for significant revenue growth from 2025.분석 기사 • May 12
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...분석 기사 • Apr 16
Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
With a price-to-sales (or "P/S") ratio of 2.1x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) may be sending bullish signals...분석 기사 • Feb 11
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The investors in Sensus Healthcare, Inc. 's ( NASDAQ:SRTS ) will be rubbing their hands together with glee today, after...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 37 | 1 | N/A | N/A | 2 |
| 12/31/2027 | 34 | -1 | N/A | N/A | 4 |
| 12/31/2026 | 23 | -6 | N/A | N/A | 4 |
| 3/31/2026 | 23 | -8 | N/A | N/A | N/A |
| 12/31/2025 | 27 | -8 | 0 | 1 | N/A |
| 9/30/2025 | 36 | -3 | 2 | 2 | N/A |
| 6/30/2025 | 38 | -1 | 3 | 4 | N/A |
| 3/31/2025 | 39 | 2 | 5 | 5 | N/A |
| 12/31/2024 | 42 | 7 | -1 | -1 | N/A |
| 9/30/2024 | 41 | 9 | 2 | 3 | N/A |
| 6/30/2024 | 36 | 7 | -1 | -1 | N/A |
| 3/31/2024 | 32 | 5 | -5 | -4 | N/A |
| 12/31/2023 | 24 | 0 | -2 | -2 | N/A |
| 9/30/2023 | 25 | -1 | -15 | -15 | N/A |
| 6/30/2023 | 30 | 2 | -12 | -12 | N/A |
| 3/31/2023 | 38 | 6 | -11 | -10 | N/A |
| 12/31/2022 | 45 | 24 | -2 | -1 | N/A |
| 9/30/2022 | 44 | 27 | 7 | 7 | N/A |
| 6/30/2022 | 41 | 25 | 4 | 4 | N/A |
| 3/31/2022 | 34 | 21 | 4 | 4 | N/A |
| 12/31/2021 | 27 | 4 | 0 | 0 | N/A |
| 9/30/2021 | 19 | 0 | 1 | 1 | N/A |
| 6/30/2021 | 15 | -2 | -3 | -3 | N/A |
| 3/31/2021 | 11 | -4 | -2 | -2 | N/A |
| 12/31/2020 | 10 | -7 | -1 | 0 | N/A |
| 9/30/2020 | 13 | -7 | 0 | 0 | N/A |
| 6/30/2020 | 17 | -6 | 1 | 1 | N/A |
| 3/31/2020 | 24 | -3 | 5 | 5 | N/A |
| 12/31/2019 | 27 | -2 | N/A | -2 | N/A |
| 9/30/2019 | 27 | -3 | N/A | -4 | N/A |
| 6/30/2019 | 27 | -2 | N/A | -5 | N/A |
| 3/31/2019 | 26 | -3 | N/A | -12 | N/A |
| 12/31/2018 | 26 | -2 | N/A | -9 | N/A |
| 9/30/2018 | 25 | -3 | N/A | -6 | N/A |
| 6/30/2018 | 23 | -3 | N/A | -5 | N/A |
| 3/31/2018 | 22 | -3 | N/A | -4 | N/A |
| 12/31/2017 | 21 | -4 | N/A | -3 | N/A |
| 9/30/2017 | 19 | -3 | N/A | -2 | N/A |
| 6/30/2017 | 18 | -2 | N/A | -3 | N/A |
| 3/31/2017 | 16 | -2 | N/A | -3 | N/A |
| 12/31/2016 | 15 | 0 | N/A | -1 | N/A |
| 9/30/2016 | 14 | 0 | N/A | -2 | N/A |
| 6/30/2016 | 13 | 0 | N/A | -1 | N/A |
| 3/31/2016 | 11 | 0 | N/A | -1 | N/A |
| 12/31/2015 | 10 | -1 | N/A | -1 | N/A |
| 9/30/2015 | 8 | -2 | N/A | -1 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: SRTS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: SRTS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: SRTS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: SRTS 의 수익(연간 20.3%)이 US 시장(연간 12.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: SRTS 의 수익(연간 20.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: SRTS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/14 14:31 |
| 종가 | 2026/06/12 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sensus Healthcare, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Scott Henry | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |